CCK-8 assay revealed that SJB3-019A inhibited cell vitality of B-ALL cells in a dose- and time- dependent manner, directly showing that USP1 may serve as a target for B-ALL therapy. This evidence concerns the gene USP1 and acute lymphoblastic leukemia.